DS-1205c + Osimertinib
Phase 1Terminated 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Non-small Cell Lung Cancer (NSCLC)
Conditions
Non-small Cell Lung Cancer (NSCLC)
Trial Timeline
Apr 10, 2019 → Sep 4, 2020
NCT ID
NCT03255083About DS-1205c + Osimertinib
DS-1205c + Osimertinib is a phase 1 stage product being developed by Daiichi Sankyo for Non-small Cell Lung Cancer (NSCLC). The current trial status is terminated. This product is registered under clinical trial identifier NCT03255083. Target conditions include Non-small Cell Lung Cancer (NSCLC).
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03255083 | Phase 1 | Terminated |
Competing Products
20 competing products in Non-small Cell Lung Cancer (NSCLC)